A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers.
| dc.contributor.author | Escudier, B | |
| dc.contributor.author | Faivre, S | |
| dc.contributor.author | Van Cutsem, E | |
| dc.contributor.author | Germann, N | |
| dc.contributor.author | Pouget, J | |
| dc.contributor.author | Plummer, R | |
| dc.contributor.author | Vergote, I | |
| dc.contributor.author | Thistlethwaite, Fiona C | |
| dc.contributor.author | Bjarnason, G | |
| dc.contributor.author | Jones, R | |
| dc.contributor.author | Mackay, H | |
| dc.contributor.author | Edeline, J | |
| dc.contributor.author | Fartoux, L | |
| dc.contributor.author | Hirte, H | |
| dc.contributor.author | Oza, A | |
| dc.date.accessioned | 2017-09-08T11:33:53Z | |
| dc.date.available | 2017-09-08T11:33:53Z | |
| dc.date.issued | 2017-08-10 | |
| dc.identifier.citation | A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. 2017 Target Oncol | en |
| dc.identifier.issn | 1776-260X | |
| dc.identifier.pmid | 28798986 | |
| dc.identifier.doi | 10.1007/s11523-017-0525-2 | |
| dc.identifier.uri | http://hdl.handle.net/10541/620550 | |
| dc.description.abstract | Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Targeted oncology | en |
| dc.title | A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. | en |
| dc.type | Article | en |
| dc.contributor.department | Oncology Department, Gustave-Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France | en |
| dc.identifier.journal | Targeted Oncology | en |
| html.description.abstract | Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors. |